Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

0.00%

4.1¢ incannex healthcare limited

General discussion, page-482

First 482 Last

Share
Profile

Follow
Exalted

1,869 Posts.

1472

08/06/20

02:11

Post #: 45090192
Share

Originally posted by dalts66: ↑

Sorry about the post above. It contains extranious stuff. i have asked for it to be removed. Here is another attempt.

Small Caps ASX Australian stock market
Weekly review: Australian share market shooting out the lights near 6000 points as dollar hits US70c
By John Beveridge - June 6, 2020
Australian market ASX 200 6000 points dollar US70c June 2020
WEEKLY MARKET REPORT
5

Impression Healthcare (ASX: IHL)
Impression Healthcare revealed it would focus exclusively on cannabinoid sales and drug development, which the company’s chief executive officer Joel Latham claims is the part of the business that drives value for shareholders.

“The opportunities in the medicinal cannabis sector are significant and [Impression] has assembled a world-class team in this space, with four clinical assets undergoing assessment,” he said.

To reflect this focus, Impression plans to change its industry classification code from Health Care Equipment and Services to Pharmaceuticals, Biotechnology and Life Sciences.

Additionally, Impression proposes to change its name to its medicinal cannabis brand Incannex Healthcare Ltd.

The new focus follows Impression kicking-off trials to assess the impact of its cannabidiol (CBD) drug IHL-675A against COVID-19 induced associated acute respiratory distress syndrome (SAARDS), which is the primary cause of death in severe COVID-19 patients.

Under the first stage of the trial, the drug will be used on rodents with induced sepsis. Results from stage one will then underpin the next stage which will investigate the “optimal inflammation dampening response” of the drug.

If the studies prove successful, then Impression will apply to the US FDA for Emergency Use Authorisation, which will enable testing in human COVID-19 patients.

Expand

Looks like we will see notice of the TGA changing CBD from prescription only under SAS to OTC.
I am certain that Cannvalate and IHL are eyeing this closely, could make our oils sales explode!
I also recall that our clinical trial related drugs can be sold under SAS immediately, is it possible that if these changes go through that IHL will be able to sell its novel IP related drugs OTC across pharmacies and drug stores country wide?
Wednesday will be very interesting.

Last edited by Exalted: 08/06/20

IHL Price at posting: 5.2¢ Sentiment: Buy Disclosure: Held
20 Upvote

3 Great analysis

Reply

Top Stories

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

YAL

Yancoal makes it into the ASX200 in latest S&P rebalance

GDC

Global Data Centres not clear on future operations after AirTrunk sale payout

CNB

Carnaby Resources hits copper at Mohawk, QLD

CBL

Control Bionics expands into UK and Irish markets with NeuroNode device